Fingerprint
Dive into the research topics of 'Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab
David Chu, Michelle Stevens, Douglas Edward Gladstone
Research output: Contribution to journal › Article › peer-review
8
Scopus
citations